IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

NCT07509086 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma
Plasma Cell Leukemia (PCL)

Interventions

BIOLOGICAL: IL-15-armored CAR-T cells

Sponsor

The First Hospital of Jilin University